Benactiv Throat Mouthwash 2.5mg/ml Flurbiprofen 160ml

Benactiv Throat Mouthwash 2.5mg/ml Flurbiprofen 160ml

RECKITT BENCKISER

SKU
033262015
Special Price €7.43 Regular Price €10.10 Save... €2.67 -26%
Recent lowest price:   €7.30
Out of stock

Flurbiprofen -based mouthwash.

Therapeutic indications

Benactiv Gola is used in the symptomatic treatment of irritative-inflammatory states also associated with pain in the oropharyngeal cavity (eg gingivitis, stomatitis, pharyngitis), also as a consequence of conservative or extractive dental therapy.

Dosage and Posology

The drug should be taken according to the following doses and methods: 2-3 rinses or gargles a day with 10 ml (1 scoop) of mouthwash diluted in half a glass of water or pure.

Overdose

Considering the reduced content of active ingredient and its local use, it is unlikely that overdose situations will occur.

Symptoms of overdose may include nausea, vomiting and gastrointestinal irritation. Treatment should include gastric lavage and, if necessary, correction of the serum electrolyte picture. There is no specific antidote for flurbiprofen.

Contraindications

  • Do not use in children under 12 years of age.
  • Flurbiprofen is contraindicated in patients with known hypersensitivity (asthma, urticaria or allergic type) to flurbiprofen or to any of the excipients, and to aspirin or other NSAIDs.
  • Flurbiprofen is also contraindicated in patients with a history of gastrointestinal bleeding or perforation related to previous NSAID treatment.
  • Flurbiprofen should not be taken by patients with active or anamnestic ulcerative colitis, Crohn's disease, recurrent peptic ulcer or gastrointestinal bleeding (defined as two or more distinct episodes of proven ulceration or bleeding).
  • Flurbiprofen is contraindicated in patients with severe heart failure.
  • Third trimester of pregnancy.

Side effects

The following undesirable effects have been reported, particularly after administration of formulations for systemic use:

  • Blood and lymphatic system disorders: Thrombocytopenia, aplastic anemia and agranulocytosis
  • Immune system disorders: Anaphylaxis, angioedema, allergic reaction
  • Nervous system disorders: Dizziness, cerebrovascular accidents, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, dizziness, discomfort, fatigue and somnolence
  • Acoustic and labyrinth disorders: Tinnitus
  • Respiratory, thoracic and mediastinal disorders: Respiratory tract reactivity (asthma, bronchospasm and dyspnoea)
  • Gastrointestinal Disorders: The most commonly observed adverse events are gastrointestinal in nature. Nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease have been reported following administration of flurbiprofen. ulcer perforation and bleeding.
  • Skin and subcutaneous tissue disorders: Skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatosis (including Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis and Erythema multiforme).
  • Renal and urinary disorders: Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported.

The topical use of the product, especially if prolonged, can give rise to sensitization or local irritation phenomena. The dissolution in the oral cavity of the product in the form of tablets may be accompanied by sensations of heat or tingling in the oropharynx. In such cases, treatment must be interrupted and appropriate therapy instituted if necessary

Pregnancy and breastfeeding

During the first and second trimester of pregnancy, flurbiprofen should not be administered except in strictly necessary cases. Administration of flurbiprofen is not recommended in nursing mothers

Special warnings

At the recommended doses, when using the product in its various pharmaceutical forms, any swallowing does not cause any harm to the patient, as the dose of flurbiprofen is much lower than that commonly used in systemic treatments. The use of the product, especially if prolonged, can give rise to sensitization phenomena or local irritation; in such cases it is necessary to interrupt the treatment and consult the doctor to establish, if necessary, a suitable therapy. In patients with renal, cardiac or hepatic insufficiency the product should be used with caution. It is advisable not to associate the product with other NSAIDs. Cases of bronchospasm have been reported with flurbiprofen in patients with a history of bronchial asthma.

Flurbiprofen should be administered with caution to patients with a history of peptic ulcer and other gastrointestinal diseases as these conditions may be exacerbated. The risk of gastrointestinal bleeding, ulcer or perforation is higher with increasing flurbiprofen dosage in patients with a history of ulcer, particularly if complicated with haemorrhage and perforation and in the elderly. These patients should start treatment with the lowest available dose. Gastrointestinal bleeding, ulcer or perforation have been reported with all NSAIDs at any time during treatment. These adverse events can be fatal and can occur with or without warning symptoms or with a previous history of serious gastrointestinal events. Patients with a history of gastrointestinal disease, particularly if elderly, should report any unusual abdominal symptoms (especially gastrointestinal bleeding) in the initial stages of treatment. Elderly patients have an increased frequency of adverse reactions to NSAIDs, especially gastrointestinal haemorrhage and perforation, which can be fatal. Undesirable effects can be minimized by using the lowest effective dose for the shortest possible duration of treatment needed to control symptoms.

Benactiv Gola Collutorio and Benactiv Gola Spray contain para-hydroxy-benzoates which can cause delayed allergic reactions, such as contact dermatitis; more rarely they can cause immediate reactions, with hives and bronchospasm.

Expiration and retention

Check the expiration date indicated on the package. The expiry date indicated on the package refers to the product in intact packaging, correctly stored.

Warning : do not use the medicine after the expiry date indicated on the package.

Composition

100 ml of Benactiv Throat Mouthwash contain:

Active principle

Flurbiprofen 250 mg

Excipients

Glycerol, ethyl alcohol, sorbitol 70, hydrogenated castor oil-40-polyoxyethylenate, sodium hydroxide, sodium saccharinate, methyl parahydroxybenzoate, propyl parahydroxybenzoate, mint essence, patent blue V (E 131), purified water.

Destination Cost Detail
Italy €5,90 24/48 h
Austria, Belgium, France, Germany, Netherlands, Poland, Czech Republic € 12* 3 days
Denmark,Luxembourg,Portugal,Slovakia,Spain,Hungary € 16* 4 days
Bulgary,Croatia,Estonia,Finland,Greece,Ireland,Lithuania,Romania,Slovenia,Sweden € 27* 5 days
Canada, Switzerland, United Kingdom, USA € 45 7 Days

National shipments with express courier: Bartolini, GLS
European shipments with express courier: FedEx, MBE, DHL
*For the shipment outside band B ther's an extra cost of 20€
*For the shipment outside band C ther's an extra cost of 30€
Delivery Times exclude Saturday and Holidays
For Islands and Areas of difficult Accessibility the shipments are made in 72 hours and the cost will be increased by 15€
The images of the products shown on our site are purely indicative and may differ in shape, color, text and packaging shown on them. Given the difficulty of updating all the products on our site in real time or any errors, XFarma.it, all products will be identified through SKU MINSAN (code of the Ministry of Health).